SLC5A2 and type 2 diabetes mellitus: In the SURPASS-3 trial, once-weekly Tirzepatide was compared with once-daily insulin degludec as an add-on to metformin with or without inhibitors of Sodium/Glucose Transporter 2 (SGLT2) in patients with T2DM not adequately controlled [44].